Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Biopharmaceutical Reimbursement Experts (EU)

Articles with lock require a subscription to GLG News | Request a free trial
October 24, 2007
Exubera - approvable is no longer reimbursable
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: David Sykes, Principal, PRMA Consulting Ltd.
Exubera is the first major product to fail primarily due to Pfizer's inability to convince payors of it's value for money There is now significant additional risk in achieving market access after regulatory approval. Pricing and reimbursement decisions will play an increasingly important role in the...
June 18, 2007
Th
Analysis of: FDA Advisory Committee Did Not Recommend Approval of Rimonabant (ZIMULTI(R)) for Use in Obese and Overweight Patients With Associated Risks Factors | www.pipelinereview.com
Author: GLG Expert Contributor
This is a severe blow for the company which is now forced to consider external growth, but is not expert in out-of-France acquisitions. Rimonabant was meant to become THE sanofi-aventis blockbuster for the next 5 years at least. Also, the R&D productivity at sanofi-aventis will be questioned, since...

Page : 11 to 2 of 2

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773